StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Jefferies Reiterates Buy Rating and $140 PT on Incyte Corp. (INCY); EU Bari Label In-Line
February 17, 2017 8:37 AM
Jefferies analyst Brian Abrahams reiterates Buy rating and $140 price target on Incyte Corp. (NASDAQ: INCY), noting no major updates ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
FDA
Next Articles
Lilly (LLY) and Incyte (INCY) Announces Additional Results from Pivotal RA-BEAM Study Published in NEJM
February 16, 2017 7:35 AM
Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal
February 15, 2017 5:57 PM
Incyte (INCY) PT Raised to $140 at Jefferies on 4Q Report, Jakafi Metrics
February 15, 2017 8:10 AM
Incyte (INCY) PT Raised to $138 at RBC Capital Citing Growth in Jakafi
February 15, 2017 7:36 AM
Incyte (INCY): Raising PT On Additional Sources of Upside - BMO
February 15, 2017 6:15 AM
